Preventing perinatal transmission of HIV : Costs and effectiveness of a recommended intervention.
To calculate the national costs of reducing perinatal transmission of human immunodeficiency virus through counseling and voluntary testing of pregnant women and zidovudine treatment of infected women and their infants, as recommended by the Public Health Service, and to compare these costs with the savings from reducing the number of pediatric infections.
The authors analyzed the estimated costs of the intervention and the estimated cost savings from reducing the number of pediatric infections.
The outcome measures are the number of infections prevented by the intervention and the net cost (cost of intervention minus the savings from a reduced number of pediatric HIV infections).
The base model assumed that intervention participation and outcomes would resemble those found in the AIDS Clinical Trials Group Protocol 076.
Assumptions were varied regarding maternal seroprevalence, participation by HIV-infected women, the proportion of infected women who accepted and completed the treatment, and the efficacy of zidovudine to illustrate the effect ofthese assumptions on infections prevented and net cost.
Without the intervention, a perinatal HIV transmission rate of 25% would result in 1750 HIV-infected infants born annually in the United States, with lifetime medical-care costs estimated at $282 million.
The cost of the intervention (counseling, testing, and zidovudine treatment) was estimated to be $67.6 million. (...)
Mots-clés Pascal : SIDA, Virose, Infection, Transmission, Mère, Gestation, Nourrisson, Homme, Dépistage, Chimiothérapie, Traitement, Zidovudine, Antiviral, Prévention, Analyse coût efficacité, Economie santé, Etats Unis, Amérique du Nord, Amérique, Immunopathologie, Immunodéficit
Mots-clés Pascal anglais : AIDS, Viral disease, Infection, Transmission, Mother, Pregnancy, Infant, Human, Medical screening, Chemotherapy, Treatment, Antiviral, Prevention, Cost efficiency analysis, Health economy, United States, North America, America, Immunopathology, Immune deficiency
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0389340
Code Inist : 002B30A03B. Création : 10/04/1997.